Home » FDA Approves Focalin XR to Treat ADHD in Adults, Adolescents and Children
FDA Approves Focalin XR to Treat ADHD in Adults, Adolescents and Children
Focalin XR (dexmethylphenidate HCl), developed jointly by Novartis Pharmaceuticals and Celgene, has been approved by the FDA as a treatment for attention-deficit/hyperactivity disorder (ADHD) in adults, adolescents and children.
The approval was based on efficacy and safety data from clinical trials involving approximately 320 adults, adolescents and children diagnosed with ADHD.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct